(RTTNews) - Hoth Therapeutics, Inc. (HOTH) reported proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The company said a significant decline in Aß was seen in the Alzheimer's disease mouse model after acute treatment with HT-ALZ.
Alzheimer's disease is a neurodegenerative disease that is characterized by aggregates of amyloid ß (Aß) plaques and neurofibrillary tangles of Tau protein in the brain. HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.
Shares of Hoth Therapeutics were up 43% in pre-market trade on Tuesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
